Company / Revenue
AMICUS THERAPEUTICS, INC. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$634.2M
FY2025
5-year range
$305.5M / $634.2M
FY2021-FY2025
Trend
+20.0%
vs FY2024
Sector context
#57 of 155
Health Care
What the data says
At $634M, AMICUS THERAPEUTICS, INC.'s revenue ranks #57 of 155 in the Health Care sector. Revenue has increased for 8 consecutive years, from $5M in FY2016 to $634M in FY2025.
Based on SEC 10-K filings.
$634M in FY2025 with a 5-year CAGR of +19.4%.
Improved from $399M to $634M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +24.4%
- 5-Year CAGR
- +19.4%
- 10-Year CAGR
- -
Sector benchmark
#57 of 155 in Health CareTop 37% of 155This company $634.2M Sector average $4.5B
▼
-85.8% below sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s revenue has grown for 6 consecutive years.
- 5-year CAGR of +19.4%, indicating consistent growth.
- In FY2025, revenue increased 20.0% year-over-year.
- Ranks #57 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $634.2M | +20.0% |
| FY2024 | $528.3M | +32.3% |
| FY2023 | $399.4M | +21.3% |
| FY2022 | $329.2M | +7.8% |
| FY2021 | $305.5M | +17.1% |
| FY2020 | $260.9M | +43.2% |
| FY2019 | $182.2M | - |
| FY2018 | - | - |
| FY2017 | $36.9M | +644.9% |
| FY2016 | $5.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026